Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Randall E. Brand

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4136-3313; OpenAlex author ID A5039387801; NIH RePORTER profile ID 8645623. Sources: ClinicalTrials.gov.

Their work

Papers
101 (first author 7, last author 19)
Trials
2 (principal investigator on 2)
Grants
8
Labs led
2
Collaborators
399
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 7 papers · 2012: 4 papers · 2013: 4 papers · 2014: 4 papers · 2015: 4 papers · 2016: 5 papers, 1 trial · 2017: 5 papers · 2018: 7 papers · 2019: 12 papers · 2020: 8 papers · 2021: 7 papers, 1 grant · 2022: 7 papers · 2023: 3 papers, 2 grants · 2024: 9 papers · 2025: 6 papers, 2 grants · 2026: 9 papers, 3 grants

Papers 50 of 101

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Co-author DOI 10.1002/ijc.70592↗
  2. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  3. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. Last author DOI 10.1016/j.pan.2026.05.004↗
  4. High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis. Co-author DOI 10.1021/acs.analchem.5c01928↗
  5. Machine learning-based multimodal biomarkers enable accurate diagnosis and early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29548-4↗
  6. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2025.08.034↗
  7. Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups. Co-author DOI 10.1186/s12885-026-16058-3↗
  8. A Biomarker Panel for the Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18091397↗
  9. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… Last author DOI 10.3390/jcm15197355↗
  10. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis. Co-author DOI 10.1007/s00125-025-06543-y↗
  11. Reply to the Letter to the Editor regarding “Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early … Co-author DOI 10.1016/j.pan.2025.04.017↗
  12. Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples. Co-author DOI 10.1126/sciadv.adt0029↗
  13. Plant-Based Dietary Index and Risk of Pancreatic Cancer: Findings from a Prospective Cohort Study. Co-author DOI 10.1158/1055-9965.epi-25-1060↗
  14. A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals. Last author DOI 10.3390/cancers17111866↗
  15. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/curroncol32110638↗
  16. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  17. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Last author DOI 10.1002/cncr.35383↗
  18. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Last author DOI 10.1016/j.canlet.2024.217245↗
  19. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Co-author DOI 10.1016/j.gastha.2024.08.002↗
  20. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  21. Differential extracellular vesicle concentration and their biomarker expression of integrin αv/β5, EpCAM, and glypican-1 in pancreatic cancer models. Co-author DOI 10.1038/s41598-024-65209-8↗
  22. Tryptophan intake and pancreatic cancer: findings from a case-control study. Co-author DOI 10.1097/cej.0000000000000864↗
  23. Pancreatic Cysts Greater Than 1 cm Are Associated With an Increased Risk for Developing Pancreatic Cancer in Individuals From Pancreatic-Cancer Prone Kindreds … Last author DOI 10.1097/mpa.0000000000002312↗
  24. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  25. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. First author DOI 10.1053/j.gastro.2023.02.012↗
  26. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  27. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  28. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  29. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  30. Pancreatic Cancer Surveillance and Novel Strategies for Screening. First author DOI 10.1016/j.giec.2021.08.008↗
  31. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  32. Composite Score of Healthy Lifestyle Factors and the Risk of Pancreatic Cancer in a Prospective Cohort Study. Co-author DOI 10.1158/1940-6207.capr-21-0205↗
  33. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  34. The Association between Serum Serine and Glycine and Related-Metabolites with Pancreatic Cancer in a Prospective Cohort Study. Co-author DOI 10.3390/cancers14092199↗
  35. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  36. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  37. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  38. Quality Diet Index and Risk of Pancreatic Cancer: Findings from the Singapore Chinese Health Study. Co-author DOI 10.1158/1055-9965.epi-21-0033↗
  39. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  40. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-20-0303↗
  41. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter First author DOI 10.1158/1940-6207.capr-21-0233↗
  42. Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and w… Co-author DOI 10.1016/j.pan.2019.11.008↗
  43. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  44. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  45. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  46. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  47. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Co-author DOI 10.1158/1055-9965.epi-20-0161↗
  48. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  49. Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients. Co-author DOI 10.3390/cancers12061534↗
  50. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗

Trials 2

  1. Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer Principal investigator NCT02790944↗
  2. Pancreatic Adenocarcinoma Gene Environment Risk Study Principal investigator NCT00912717↗

Grants 8

  1. Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma U01CA200466↗
  2. Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions U01CA274514↗
  3. UPMC Clinical Center for the Study of Chronic Pancreatitis and Diabetes U01DK108306↗
  4. Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer R01CA254036↗
  5. PancreasFest 2025: Pancreas Disease Across the Lifespan R13DK145190↗
  6. PancreasFest 2023 R13DK137547↗
  7. Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers U01CA226158↗
  8. Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers U01CA152653↗

Closest collaborators

The 25 strongest of 399 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 9 shared papers, 2 shared grants, 2011–2026 · strength 2.69
  2. Michael Goggins · 17 shared papers, 2016–2025 · strength 1.95
  3. Aatur Dilip Singhi · 14 shared papers, 2017–2026 · strength 1.87
  4. David Clement Whitcomb · 15 shared papers, 1 shared grant, 2011–2026 · strength 1.76
  5. Fay Kastrinos · 13 shared papers, 2019–2026 · strength 1.74
  6. Elena M. Stoffel · 14 shared papers, 2016–2024 · strength 1.54
  7. Dhiraj Yadav · 5 shared papers, 1 shared grant, 2018–2026 · strength 1.52
  8. Anirban Maitra · 12 shared papers, 2017–2026 · strength 1.45
  9. Diane M. Simeone · 11 shared papers, 2011–2026 · strength 1.42
  10. Daniel W. Chan · 2 shared papers, 1 shared grant, 2026 · strength 1.40
  11. Hui Zhang · 2 shared papers, 1 shared grant, 2026 · strength 1.40
  12. Lynette M. Smith · 10 shared papers, 2011–2026 · strength 1.35
  13. Walter Gwang-Up Park · 9 shared papers, 2018–2026 · strength 1.35
  14. Bryson W. Katona · 9 shared papers, 2021–2026 · strength 1.35
  15. Beth Dudley · 8 shared papers, 2018–2026 · strength 1.29
  16. Christine Worthington · 5 shared papers, 2024–2026 · strength 1.22
  17. Brian B. Haab · 2 shared grants, 2021–2023 · strength 1.22
  18. Aimee Lee Lucas · 9 shared papers, 2019–2026 · strength 1.18
  19. Zhen Zhang · 1 shared paper, 1 shared grant, 2026 · strength 1.13
  20. Thomas Charles King · 5 shared papers, 2022–2026 · strength 1.10
  21. Anna E. Lokshin · 3 shared papers, 1 shared grant, 2011–2025 · strength 1.08
  22. Amer H. Zureikat · 8 shared papers, 2018–2026 · strength 1.08
  23. Frederico G. S. Toledo · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.07
  24. Marcia Irene Canto · 10 shared papers, 2018–2024 · strength 0.98
  25. Norma Alonzo Palma · 4 shared papers, 2025–2026 · strength 0.96

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.